在聚光灯下
Mechanisms of inflammation and tissue remodelling in chronic diseases
Decarbonising respiratory care requires us to deliver care differently
呼吸 & Immunology
Our ambition is to transform 呼吸 & 对患者的免疫护理, moving beyond symptom control to disease modification, 缓解与, one day, cure.
Home / 澳门葡京赌博游戏的治疗领域 /呼吸 & Immunology
澳门葡京赌博游戏的承诺
有五十年的经验, we are an established leader in respiratory care and a disruptor in immunology. 澳门葡京赌博游戏致力于改变对一些最使人衰弱的慢性呼吸道疾病和免疫介导疾病的护理. Our portfolio of inhaled and biologic medicines, 以及澳门葡京赌博游戏未来的管道, seek to address the challenges and vast unmet medical needs patients face today. 通过遵循科学, we are focused on sustainably addressing tough and complex unsolved problems. 澳门葡京赌博游戏的方法 involves targeting the underlying biology, 开发有效的新药物模式和组合，并从发现药物开始应用精准医学方法, 一切都是在驾驶时提前发现的, 诊断与干预.
澳门葡京赌博游戏的重点领域
澳门葡京赌博游戏专注于慢性呼吸系统疾病，包括哮喘和慢性阻塞性肺疾病(COPD)。, as well as immune-driven diseases such as lupus. We follow the science to address tough and complex, 未解决的问题-以潜在生物学为目标，开发有效的新药物模式和组合，最终实现疾病改变和临床缓解.
Click on the links below to learn more about our focus areas:
Our people
澳门葡京赌博游戏是呼吸医学领域的领导者，也是免疫学领域的颠覆者，澳门葡京赌博游戏投资并重视澳门葡京赌博游戏的员工. We are positioned to follow the science in our research, while also solving issues in treatment and management of respiratory and immune-mediated diseases. 澳门葡京赌博游戏的文化植根于诚信, 包容, and our dedication to joining and supporting the communities in which we live and work.
呼吸 & 免疫学团队由:
It is an exciting time to work in 呼吸 & Immunology, 随着澳门葡京赌博游戏继续努力改变对一些最使人衰弱的慢性呼吸道和免疫介导疾病的护理. 从发现药物的一开始，就以潜在的生物学为目标，应用精准医学方法, we aim to move beyond symptom control to disease modification, 缓解和一天, cure.
协作
通过合作和伙伴关系，澳门葡京赌博游戏可以加速为患者带来积极的变化和结果. We work with leading research and academic institutions, 公共卫生当局, patient groups and professional organisations across respiratory and immune-mediated diseases.
国际呼吸联盟
As part of our commitment to transform respiratory care for all patients, we are a founding partner of the 国际呼吸联盟. 该联盟旨在支持大流行后呼吸道保健的转变，到2030年将全球呼吸道疾病死亡人数减少三分之一. This goal, 这与联合国可持续发展目标即将到来的最后期限相一致1, 是否可以通过制定或更新国家呼吸战略来实现，从而加速并扩大良好实践护理模式的采用.
为COPD大声疾呼
The world can no longer afford to overlook COPD.2 正因为如此，澳门葡京赌博游戏正在与世界各地的主要呼吸道组织和患者盟友合作，使这一疾病成为公共卫生重点. 这项跨行业和多方合作的运动有一个关键目标:提高决策者和卫生保健系统对慢性阻塞性肺病的认识和理解. Together we are aiming to unlock policy change barriers that can optimise COPD care.
Breathless
While important progress has been made in our understanding of severe asthma, 仍有大量需求未得到满足，太多的人得不到应有的治疗和护理.3,4 通过提高对严重哮喘对患者生命持续影响的新证据的认识，并将这些挑战与切实的良好实践案例研究解决方案联系起来, 这项运动的目的是促使决策者和卫生保健专业人员采取紧急措施，帮助解决导致不理想护理的障碍.
打破过分依赖
澳门葡京赌博游戏的药品
We cannot provide detailed information about our prescription medicines on this website, 遵守规定.澳门葡京赌博游戏的药物在个别国家获得了特定用途的批准，澳门葡京赌博游戏为患者提供的信息受当地法规的约束. 在某些情况下, 医疗保健专业人员和患者可以访问当地的澳门葡京网赌游戏网站，以了解有关澳门葡京赌博游戏药物的更多信息. Please note that in some countries we are not allowed to provide very much, 有时是任何, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
accolit, accolit, Vanticon
zafirlukast
Bevespi大气层
格隆/ formoterol延胡索酸酯
Breztri大气层
budesonide/格隆/ formoterol延胡索酸酯
Bricanyl Respules
特布他林
Bricanyl Turbuhaler
特布他林 in a dry powder inhaler
Daliresp / Daxas
roflumilast
Duaklir Genuair
aclidinium / formoterol
Eklira Genuair / Tudorza / Bretaris
aclidinium，一个LAMA
Fasenra
benralizumab
Oxis Turbuhaler
Oxis Turbuhaler
急性喘息性
布地奈德吸入混悬液
Pulmicort Turbuhaler
budesonide
Rhinocort
budesonide
Saphnelo
anifrolumab
Symbicort pMDI
布地奈德/ formoterol
Symbicort Turbuhaler
布地奈德/ formoterol
Tezspire
tezepelumab
R的管道&I
澳门葡京赌博游戏的产品线在临床开发的不同阶段形成了强大的研究性治疗组合.
第三阶段/注册. 指处于第三阶段或已提交监管机构批准的资产，可能包括目前在一个或多个主要市场推出的资产.
呼吸 & 免疫学(截至2024年4月25日)
Phase I
Phase I
Phase II
Phase III
Phase III
模块项目
模块项目
最新消息
References
1. 联合国. 可持续发展目标. 可在:http://www.un.org/sustainabledevelopment/sustainable-development-goals/. [最后访问日期:2022年8月].
2. 世界卫生组织. 慢性阻塞性肺病字幕新闻. 可在:http://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). [最后访问日期:2022年8月].
3. Chen S, et al. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. 当前医学研究意见. 2018;34:2075–2088
4. Peters SP, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006: 100 (7): 1139-51.
Veeva ID: Z4-51416
筹备日期:2022年12月